Abstract Objective: Techniques for surgical repair of Trans-Atlantic Inter-Society Consensus (TASC) C and D lesions of the superficial femoral artery (SFA) are supragenicular bypass grafting or the less invasive remote endarterectomy (RSFAE). This trial compares the patency rates of both techniques. Design: Randomized, multicenter trial. Materials and methods: 116 patients were randomized to RSFAE (n Z 61) and supragenicular bypass surgery (n Z 55). Indications for surgery were claudication (n Z 77), rest pain (n Z 21), or tissue loss (n Z 18). Results: Median hospital stay was 4 days in the RSFAE group compared with 6 days in the bypass group (p Z 0.004). Primary patency after 1-year follow-up was 61% for RSFAE and 73% for bypass (p Z 0.094). Secondary patency was 79% for both groups. Subdividing between venous (n Z 25) and prosthetic grafts (n Z 30) shows a primary patency of 89% and 63% respectively at 1-year follow-up (p Z 0.086). Conclusion: RSFAE is a minimally invasive adjunct in the treatment of TASC C and D lesions of the SFA, with shorter admittance and a comparable secondary patency rate to bypass. The
Introduction
Different treatment modalities exist for Trans-Atlantic Inter-Society Consensus 1 (TASC) C and D lesions of the superficial femoral artery (SFA). Every possible procedure still has a significant reobstruction rate, which might result in major lower limb amputation. Patency rates for percutaneous transluminal angioplasty (PTA) are discouraging. 2 The use of additional stents has not improved these results. 3 Subintimal angioplasty is only performed with acceptable patency rates in specialized centres. 4 The most implemented and established procedure for treatment of TASC C and D SFA obstructions is prosthetic or venous bypass grafting, with patency rates of 39e57% for prosthetic and 70e77% for venous bypass grafts. 5e10 An alternative surgical technique has been developed since 1994, the remote SFA endarterectomy (RSFAE). 11, 12 Patency rates of retrospective studies so far are promising, with reported patency rates of 61e69% at 18e33 months. 13 Furthermore, this procedure might offer several advantages over bypass surgery, including shorter hospital stay and fewer wound-related problems. To compare patency rates of both surgical techniques, the randomized Remote Endarterectomy Versus Above-knee bypass Surgery (REVAS) trial was performed and short-term results are reported in this article.
Materials and Methods

Study design
Study inclusion was between October 2004 and March 2007 in 1 university medical centre and 3 major teaching hospitals. The randomization of the study is closed.
Included were consecutive patients presenting with severe claudication, critical ischemia, or tissue loss (Rutherford category 3e5) 14 with a TASC C or D lesion of the SFA and a patent popliteal P1 segment with at least 1 crural runoff vessel. Only patients with chronic (>6 months) complaints originating from atherosclerotic disease were included.
Exclusion criteria were previous surgery or PTA with additional stent placement of the target SFA and a SFA diameter <4 mm. 15 Heavily calcified vessels were not excluded.
The treating vascular surgeon established the feasibility of patients by checking the inclusion criteria. All indications for revascularization were discussed in a multidisciplinary team. Randomization was done at a central telephone number, using sealed envelopes, in a permuted-block sequence and balanced by participating centre. The vascular surgeons were completely blinded on the sequence of the randomization list. Patients were randomly assigned to RSFAE or bypass with the ipsilateral saphenous vein.
When the saphenous vein was not available or, when the vein was of inadequate diameter, patients received a polytetrafluoroethylene graft (PTFE bypass â , W.L. Gore and Associates, Inc., Flagstaff, AZ, USA).
The primary endpoint was the primary patency at 5 years. This article is an interim report, presenting shortterm results. Secondary endpoints were assisted primary patency, secondary patency, limb-salvage, operation time, postoperative complications, and hospital stay. Moreover, possible prognostic factors concerning the primary patency for both study arms will be analysed.
Patency is defined in conformity with the guidelines by Rutherford et al.
14 Primary patency is defined as uninterrupted patency without any procedures performed on the treated segment. Assisted primary patency is the situation in which patency was never lost but maintained by prophylactic intervention. Secondary patency is restored patency after occlusion, excluding redo or secondary reconstruction operations that do not preserve most of the original graft and at least 1 anastomosis.
Patency was determined by duplex ultrasound imaging. A stenosis was considered significant if the peak systolic velocity ratio exceeded 2.5 or the end-diastolic velocity was higher than 60 cm/s. 14 The medical ethics board of all participating hospitals approved the study protocol. Informed consent was obtained from all patients. This study is registered with ClinicalTrials.gov, number NCT00566436.
Procedure
The preoperative evaluation consisted of medical history, including risk factors; physical examination, including peripheral pulses; ankle-brachial indices (ABIs), and a treadmill test; color flow duplex ultrasound scanning; and a magnetic resonance angiography (MRA), including crural outflow and mapping of the ipsilateral greater saphenous vein. The decision whether the greater saphenous vein was applicable for grafting (diameter >3.0 mm) 16 was made during preoperative venous mapping using a tourniquet and also assessed during surgery.
General
Vascular surgeons who had executed RSFAE previously in at least 10 patients, and venous and prosthetic bypasses in 30 patients, performed all the surgical procedures. Ceftriaxone (2 g) was administered intravenously, general or regional anesthesia was used, and the patient underwent systemic heparinization (5000 IE) before the femoral artery was excluded from circulation.
RSFAE
Exposure of the common femoral, superficial femoral, and profunda femoris arteries through a single groin incision. Arteriotomy in the proximal SFA followed by dissection of the intima core beyond the occluded SFA segment using the Vollmar ring stripper (Vollmar Dissector, Aesculap â , South San Francisco, CA, USA) under fluoroscopic guidance. The ring stripper is exchanged for a Mollring Cutter (Mollring Cutter â , LeMaitre Vascular, Inc., Burlington, MA, USA), with which transection of intima core is done remote from the site of entry (Fig. 1) . After removal of the intima core, the transection zone is passed by a 0.035-inch. Terumo guidewire (Terumo â , Terumo Corporation, Tokyo, Japan) and secured with an aSpire stent (aSpire stent â , LeMaitre Vascular, Inc., Burlington, MA, USA). This stent has a PTFEcovered nitinol framework with a DNA helical structure, offering the possibility of preserving collaterals. It is flexible and has high radial strength that makes it eligible for use in proximity of the knee joint with its torsion and flexion forces. By means of a completion arteriography, eventual distal thromboemboli can be verified and embolectomy performed if necessary. A common femoral and profunda femoris endarterectomy can be performed, and the arteriotomy may be closed with or without patch.
Bypass surgery
Vertical groin and supragenicular incisions, implantation of a deep-tunnelled reversed saphenous vein or PTFE graft with end-to-side anastomoses.
In case of multilevel disease a simultaneous procedure could be performed, such as PTA or endarterectomy of iliac, common femoral or popliteal arteries.
All patients were given antiplatelet therapy before the procedure consisting of acetylsalicylic acid (100 mg daily) or coumarin derivatives on indication. This regimen was continued after the operation.
Follow-up
Follow-up was scheduled at 3, 6, 12, 18, and 24 months and annually thereafter. Routine surveillance consisted of history, physical examination, ABIs, and duplex ultrasound scanning, with additional angiography or MRA as indicated. In the first year after the procedure, even asymptomatic restenoses were treated because previous studies have shown that revision of early restenoses will improve longterm patency rates. 15 
Statistical analysis
Based on a primary patency rate of 70% at 2 years and accepting a difference of 25%, it was calculated that the study needed to include 116 patients to obtain sufficient statistical power (a Z 0.05, two-sided; power Z 0.8). The study was planned as a non-inferiority trial. Data were analysed based on intention to treat. Patency rates were calculated with KaplaneMeier life-table estimates. Multivariate analysis was performed in both study arms separately, to identify prognostic factors influencing primary patency depending on operative strategy. Multivariate analysis was performed using the Cox hazard regression method. The univariate analysis, including all baseline parameters (Table 1) , served as the basis for the multivariate Cox hazard regression model. Variables showing association (p < 0.10) with the primary patency in univariate analysis were included in the multivariate analysis. Age, sex, indication for operation and outflow were included in all multivariate analyses. Results are presented as hazard ratio with exact 95% confidence interval (95% CI). A log-rank test, ManneWhitney U test, or c 2 test was used as indicated to compare both groups. A value of p < 0.05 was considered statistically significant. Statistical analysis was performed with SPSS 15.0 software (SPSS, Inc., Chicago, IL, USA).
Results
357 consecutive patients with a TASC C or D lesion of the SFA were assessed for eligibility. 118 patients were included and randomly assigned to RSFAE or bypass. Two patients were excluded from the bypass group; therefore 116 patients were included in the final analysis (Fig. 2 ). All patients were operated within 6 weeks of randomization. The randomization was conducted in a 2.5-year period. The first 6 months only the St. Antonius Hospital had been authorized to randomize patients and included 13 patients. The first year thereafter the St. Antonius Hospital included 19 patients, the University Medical Centre 22 patients, the Albert Schweitzer Hospital 15 patients, and the Amphia Hospital 2 patients. The last year of the study the inclusion was 17, 18, 7 and 3 patients respectively.
Baseline characteristics of the study population are summarized in Table 1 .
Despite randomization, significantly more patients scheduled for bypass surgery had a single vessel runoff and consequently more severe symptoms than patients scheduled for RSFAE. The bypass group had more patients with a history of TIA or stroke, and the RSFAE group had more smokers and more patients with hypercholesterolemia.
Intraoperative results
Intraoperative results are reported in Table 2 . Operation time and blood loss were not statistically different between groups. The mean length of the endarterectomized intima core was 30 cm (range, 20e44 cm). Only 25 patients (45%) in the bypass group had a sufficient saphenous vein suitable for bypass grafting. The other 30 patients received a PTFE graft. Initial technical success was 92% in the endarterectomy group versus 100% in the bypass group. Reasons for conversion in the RSFAE group were perforation of the SFA during endarterectomy (n Z 3), dissection distally from the transaction zone (n Z 1), or heavy calcification (n Z 1). These patients received either an above-knee PTFE bypass (3 patients, all with perforation) or a below-knee PTFE bypass (2 patients). During the operation, distal thromboemboli were found in 4 RSFAE patients, and all were successfully treated with embolectomy during the procedure.
Postoperative data
Postoperative data are reported in Table 3 . Postoperative haemorrhage occurred in 5 RSFAE patients (1 requiring reoperation) and in 4 bypass patients (3 reoperations). Superficial wound infection was observed in 9 RSFAE patients and 4 bypass patients, all treated with oral or intravenous antibiotics. Three RSFAE patients versus 4 bypass patients sustained a deep wound infection requiring surgical debridement. No association could be determined between post-operatively infection rate and Rutherford classification. Explantation of an infected PTFE bypass was necessary in 1 patient. Median hospital stay was significantly shorter for RSFAE: 4 days (range 1e21 days) versus 6 days (range 3e 28 days; p Z 0.004), whereas re-admittance differed not statistically significant between the two groups.
(Re)occlusion within 30 days occurred in 3 RSFAE patients and 2 bypass patients. Of the 3 RSFAE patients, 1 patient had only mild claudication symptoms (Rutherford category 2) and no reintervention was necessary, 1 patient received an infragenicular bypass, and 1 early reocclusion occurred in a RSFAE patient with a primary conversion (due to heavy calcification) to an infragenicular bypass. No vascular reconstruction could be performed, and below-knee amputation was necessary. The initial indication for this operation was gangrene (Rutherford category 5). The two patients in the bypass group with early occlusion were both successfully treated with thrombectomy. One patient in the bypass group was readmitted with persistent ischemia and underwent PTA of the popliteal artery and partial foot amputation. None of the patients died in the hospital or within 30 days after operation. x This patient suffered from a myocardial infarction and was considered unfit for surgery. 
Patency and survival
Mean follow-up was 12 months in both groups. Primary patency rate after 1 year of follow-up was 61% for RSFAE and 73% for femoropopliteal bypass (p Z 0.094). Assisted and primary patency rates were 73% and 75%, respectively (p Z 0.698). Secondary patency was 79% for both groups (p Z 0.953; Figs. 3e5). Limb salvage was 98%, with 1 major below-knee amputation performed in both groups. Subdividing between venous and prosthetic grafts shows primary patency rates of 89% and 63%, respectively, compared with 61% for RSFAE (p Z 0.086), assisted primary patency rates of 94% and 63% compared with 73% (p Z 0.104), and secondary patency rates of 94% and 63% compared with 79% (p Z 0.137) at 1 year of follow-up. Treatment of the 15 reoccluded SFA's in the RSFAE group and the 8 occluded bypasses in the bypass group is shown in Fig. 6 . Of the 9 restenoses in the RSFAE group, 8 were treated with PTA, and 1 was treated with endarterectomy of the femoral bifurcation. Restenosis was equally distributed within the SFA and was not restricted to the stent. Of the 2 stenoses in the bypass group, 1 was treated with PTA and the other had multiple stenoses and was reoperated on with a proximal patch plasty and a distal bypass jump graft to maintain patency. Stenosis in the graft was not limited to the anastomoses.
At 1-year follow-up, 5 patients had died: 4 (7%) in the RSFAE group and 1 (2%) in the bypass group. One death in the RSFAE group was related to the operation. This patient developed a saccular aneurysm of the common femoral artery (not mycotic) and underwent endovascular stent placement. This operation was complicated by recurrent septic bleeding, and the patient eventually died.
Influence of risk factors
Univariate analysis revealed that primary patency survival in the RSFAE group was not influenced by BMI, serum creatinine level, runoff, previous vascular procedures on target leg, medication, diabetes, hypertension and hypercholesterolemia, coronary artery disease, stroke or TIA, age and smoking. Sex and indication for operation showed an association with the primary patency (p < 0.10) and were consequently analysed in a Cox hazard regression model. Multivariate analysis showed only female gender as a significant predictor of reocclusion and restenosis with a hazard ratio of 3.47 (95% CI 1.17e10.35; p Z 0.025). For the bypass group, no independent risk factors influencing patency could be determined.
Discussion
This report describes the short-term results of the first randomized trial between RSFAE and supragenicular femoropopliteal bypass for TASC C and D lesions of the SFA. Although not significant, the trial results show a difference in primary patency rates in favour of bypass. The assisted primary and secondary patency rates, however, are comparable in both groups. Subdividing between vein and prosthetic grafts shows superiority for vein, with comparable primary patency rates for RSFAE and prosthetic grafts. In only 45% of patients scheduled for bypass surgery could the ipsilateral greater saphenous vein be used. A study by Johnson and Lee found that 11% of patients lacked a sufficient saphenous vein, excluding these used for previous cardiac procedures. 7 The role of preoperative venous mapping as a possible application in the preoperative decision-making, needs to be addressed further.
In the postoperative course, there were no statistically significant differences in complications between the 2 groups, although 1 patient required explantation of an infected PTFE bypass. Hospital stay, on the other hand, was significantly shorter for RSFAE: 4 versus 6 days (p Z 0.004).
Our study has several limitations. Despite randomization, significantly more patients with critical ischemia were allocated to the bypass group. In addition, more patients in the bypass group presented with a single vessel runoff. It is well established that patients presenting with claudication perform better, although this could not be demonstrated in this trial. 5, 6, 17 There were more differences between the 2 groups in baseline characteristics, with significantly more current or recent smokers and patients with hypercholesterolemia in the bypass group but fewer patients with a history of stroke or TIA. When we assessed this imbalance by use of Cox Hazard regression analysis, the adjusted patency rates remained unchanged (data not shown).
Initial technical success of the RSFAE group was high, with only 5 conversions to bypass; however, compared with recent literature, our results show a lower primary patency for RSFAE than expected. A recent report by Martin et al.
showed a primary patency rate of 70% at 30 months. 18 Knight et al. described an 84% primary patency rate at 18 months compared with 62% at the 1-year follow-up in our trial. 19 Other authors show less favourable results for RSFAE: Ali et al. reached a primary patency of only 42% after RSFAE in combination with covered endografts at 12 months 20 ; however, this study population consisted of only 18 patients. Rosenthal et al. performed a retrospective multicenter analysis of 40 patients treated with RSFAE, resulting in a primary patency rate of 69% at 18 months, and from the same authors, a multinational retrospective analysis among 210 patients revealed a primary patency of 61% at 33 months. 11, 13 Our results for bypass surgery are consistent with recent literature, with associated primary patency rates reaching 57e83% at 1 or 2 years of follow-up, depending on the used graft, with superior results for autologous vein. 2,5e10 This is however, an interim report, long-term results will have to prove durability of both procedures.
A possible explanation for the lower primary patency in the RSFAE group could be the prospective setting, in an unselected population. Remarkable in the present study is the high percentage of smokers, with current or recent smoking in 91% of patients allocated to RSFAE. The present RSFAE study population shows significant comorbidity, with 48% coronary artery disease, 25% diabetes, 21% history of stroke or TIA, 82% hypercholesterolemia, and 74% hypertension. Although the difference with other study populations is marked, an independent relation affecting patency could not be demonstrated here. 17, 18, 21 In our series, regression analysis revealed no independent risk factors predicting failure, besides female gender, influencing primary patency in the RSFAE group, with a hazard ratio of 3.47 (95% CI 1.17e10.35; p Z 0.025). Female gender as an independent risk factor has not been shown previously. An explanation could be the smaller diameter of the SFA in women, although we have no data to support this. Figure 5 KaplaneMeier survival estimate comparing secondary patency of remote superficial femoral artery endarterectomy (RSFAE) with suprageniculate femoropopliteal bypass (Log-Rank test: p Z 0.953).
Time (months)
Early restenosis within 1 year after RSFAE caused by presumed aggressive neointimal hyperplasia remains the Achilles heel of the RSFAE procedure, with 83% of restenosis detected within 1 year. 15 After the first year, the restenosis rate declines and is thought to be caused by progression of atherosclerosis rather than neointimal hyperplasia. 15 Therefore, future prevention of neointimal hyperplasia seems to be the key to successful preventing restenosis progressing to reocclusion. Recent research is focussing on this subject, with the development of gene and drug therapy, cryotherapy, drug eluting stents, endothelial cell seeding, and radiation or brachytherapy. A recent randomized trial by Tepe et al. showed promising results with balloon catheters for PTA coated with Paclitaxel. They found significantly less lumen reduction at 6 months and a remarkable lower reintervention rate at 6 and 24 months of 4% and 15%, respectively, for the Paclitaxel group versus 37% and 52% for the control group. 22 Perhaps results will improve after surgically debulking the SFA, which leaves the proliferative cells bare and therefore possibly more sensitive to drug treatment.
The role of cryoplasty is not yet defined, with conflicting results and no randomized trials performed so far. 23 Karthik et al. described a 100% restenosis rate within 1 year after PTA with additional cryoplasty for recurrent stenoses, but again, surgically debulking the SFA might improve outcome. 24 Graft material for bypasses is evolving as well. Heparinbonded Dacron grafts have been introduced to bypass the SFA, with better outcome compared with PTFE. Differences in patency rates were not significant at 5 years of followup, but limb salvage was 86% for heparin-coated Dacron versus 74% for PTFE. 5 RSFAE is a minimal invasive adjunct in the treatment of chronic long occlusions of the SFA, with significantly shorter hospital stay and comparable assisted primary and secondary patency rates to bypass surgery. However, the venous bypass is superior to both RSFAE and prosthetic bypass grafts, but only 45% of patients had a sufficient saphenous vein available. For patients lacking the saphenous vein, RSFAE could be the procedure of choice because prosthetic material can be avoided.
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